10-Q: Xilio Therapeutics Reports Q2 2026 Financials

Xilio Therapeutics files its Q2 2026 Form 10-Q, detailing increased collaboration revenue and ongoing R&D investments, while managing cash runway.

Summary

• Xilio Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026.
• The company reported increased collaboration and license revenue, reaching $18.7 million for the quarter and $31.3 million for the six months, primarily from agreements with AbbVie and Gilead.
• Research and development expenses increased to $14.6 million for the quarter and $34.4 million for the six months, driven by advancements in programs like XTX501 and masked T cell engagers.
• General and administrative expenses saw a slight increase to $7.6 million for the quarter but decreased to $14.6 million for the six months.
• The company ended the period with $136.0 million in cash and cash equivalents, anticipating sufficient funding into the first quarter of 2028.
• Significant forward-looking statements detail ongoing clinical trial plans and potential future milestones.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, reflecting progress in collaborations and pipeline development, but with significant ongoing financial needs and development risks.

Positives

• Collaboration and license revenue increased significantly, reaching $18.7 million in Q2 2026, up from $8.1 million in Q2 2025.
• The company has $136.0 million in cash and cash equivalents as of June 30, 2026.
• Xilio anticipates its current cash will fund operations into the first quarter of 2028.
• Progress is being made in advancing key programs like XTX501 and masked T cell engagers, with IND-enabling studies underway for CLDN18.2 and PSMA+STEAP1 programs.
• The company achieved a $6.0 million development milestone from AbbVie in Q2 2026.

Negatives

• The company continues to incur significant operating losses, with a net loss of $6.4 million for the quarter and $15.9 million for the six months.
• An accumulated deficit of $434.7 million exists as of June 30, 2026.
• The company expects operating losses to continue for the foreseeable future.
• The company will require substantial additional capital to finance operations and complete development of its product candidates.
• The fair value of common stock warrant liabilities increased, resulting in a $3.9 million loss for the quarter.

Risks

• The company will need to obtain substantial additional capital in the future to finance operations and complete the development of any current or future product candidates.
• The company has incurred significant operating losses since its inception and expects to incur significant losses for the foreseeable future.
• The business is highly dependent on the success of its current product candidates, which are in the early stages of development.
• Preclinical development is uncertain, and programs may experience delays or never advance to clinical trials.
• Clinical trials may encounter substantial delays, termination, or suspension, leading to increased costs and delayed revenue generation.
• Product candidates may cause undesirable or unexpectedly severe side effects.
• Reliance on third-party manufacturers and CROs carries risks of performance issues and disruptions.
• The company's ability to protect its intellectual property is crucial and subject to legal challenges and uncertainties.

Key Dates

Keywords

biotechnology, immuno-oncology, masked therapies, clinical-stage, drug development, oncology, AbbVie, Gilead